You are here

Primary Hyperoxaluria

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Biopharma Dive

clincial trials

Primary Hyperoxaluria

Flag link:

Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

EP Vantage

Primary Hyperoxaluria

Flag link:

Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1

Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1

Pharmaceutical Business Review

Dicerna Pharmaceuticals

breakthrough therapy

Primary Hyperoxaluria

Flag link:

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

CP Wire

Primary Hyperoxaluria

Flag link:

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

Primary Hyperoxaluria

Flag link: